文献速递泌尿生殖与妇科肿瘤放疗

在线自适应立体定向体部放疗用于伴下尿路症状和/或前列腺增生的局限期前列腺癌(X-SMILE)

Online adaptive stereotactic body radiotherapy for localized prostate cancer in patients with lower urinary tract symptoms and/or prostate hyperplasia (X-SMILE).
PubMed 文献 · Radiat Oncol · 2025-05-28

本研究评估每周CT或MRI引导的在线自适应SBRT在伴下尿路症状(IPSS>12)和/或前列腺增生(体积>60 mL)的中高危局限期前列腺癌患者中的安全性和有效性;主要终点为SBRT结束后3个月内≥3级泌尿生殖毒性或治疗相关中止,目标事件率低于临床可接受阈值20%,设计预期样本量为30例。

要点

  • 针对伴下尿路症状和/或前列腺增生的中高危局限期前列腺癌患者。
  • 采用每周CT或MRI引导的在线自适应SBRT。
  • 主要终点为SBRT后3个月内≥3级泌尿生殖毒性或治疗相关中止。

核心结论

  • 研究旨在评估每周CT或MRI引导在线自适应SBRT在该类患者中的安全性和有效性。

研究设计与样本

  • 单臂研究,计划入组30例中高危局限期前列腺癌患者(≤cT3a、Gleason评分≤9、PSA≤20 ng/ml),且IPSS>12和/或前列腺体积>60 mL。

主要发现

  • 主要终点为SBRT结束后3个月内≥3级泌尿生殖毒性(CTCAE V5.0)或治疗相关中止。
  • 目标事件率为3%,低于临床可接受阈值20%。

关键数值与推荐

  • 入组标准:中高危局限期前列腺癌,≤cT3a且Gleason评分≤9且PSA≤20 ng/ml,IPSS>12和/或前列腺体积>60 mL。
  • 主要终点阈值:事件率3%低于临床可接受阈值20%。
  • 统计学设计:α=0.05,把握度80%,预期样本量30例。

临床怎么用

  • 对于伴下尿路症状和/或前列腺增生的前列腺癌患者,在线自适应SBRT可能是一种减毒策略。
  • 中度至高度IPSS或明显梗阻性尿动力学异常时,预防性TURP可能获益,10-20%接受放疗的前列腺癌患者有TURP史。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Stereotactic body radiotherapy (SBRT) for localized prostate cancer offers non-inferior oncological outcomes and toxicity profiles compared to conventionally or moderately hypofractioned radiotherapy regimens, with shorter treatment durations. However, SBRT may not be suitable for all patients, particularly those with lower urogenital tract symptoms and/or prostatic hyperplasia. METHODS: This study aims to evaluate the safety and efficacy of weekly computed tomography (CT) or magnetic resonance image (MRI)-guided online adaptive SBRT in patients with intermediate to high-risk localized prostate cancer (i.e. ≤ cT3a and Gleason score ≤ 9 and PSA ≤ 20 ng/ml) who present with lower urinary tract symptoms (International Prostate Symptom Score [IPSS] > 12) and/or have prostate hyperplasia (prostate volume > 60 mL). The primary outcome measure is urogenital toxicity grade ≥ 3 within 3 months after completion of SBRT (according to CTCAE V5.0) or treatment-related discontinuation. Our aim is to show an event rate of 3% below a clinically acceptable threshold which is set at 20%. Under the null hypothesis, this design with an alpha of 0.05 and power of 80% results in an expected number of cases of 30. DISCUSSION: In cases of moderate to high IPSS or significant obstructive urodynamics, a pre-emptive transurethral resection of prostate (TURP) may be beneficial. Notably, 10-20% of prostate cancer patients receiving radiotherapy patients have a history of TURP. While TURP can improve obstructive symptoms, its impact on late toxicity, particularly in SBRT, requires further investigation. To mitigate the risk of urogenital toxicity, especially in the case of patients with lower urogenital tract symptoms and/or prostatic hyperplasia, emerging approaches like MR-guided adaptive SBRT and weekly SBRT have shown promise. TRIAL REGISTRATION: ClinicalTrials.gov/NCT06834152. PROTOCOL VERSION: Version 6.0.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Kroese T, Andratschke N, Belka C, et al. Online adaptive stereotactic body radiotherapy for localized prostate cancer in patients with lower urinary tract symptoms and/or prostate hyperplasia (X-SMILE). Radiat Oncol. 2025. PMID: 40437508. doi:10.1186/s13014-025-02653-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。